“Three-Parent IVF” Might Open the Door to Human Genome Editing
By Diana Bowman, Karinne Ludlow, Walter Johnson,
Slate
| 12. 01. 2020
On Oct. 19, a team of researchers from Greece and Spain made a remarkable announcement: They had started six pregnancies using a new genetic technology, mitochondrial donation. This was not the first time the technology had been used, but it is the first clinical trial approved by a government. In this case, Greek regulators approved the trial back in 2016 for assisted reproduction. Now the team has reported that four live births have resulted from the trial, with at least one more pregnancy ongoing. While that number may seem small, he outcome is notable. Of the 25 women enrolled in the trial, all of whom had struggled to become pregnant even after several IVF attempts, almost one-quarter could successfully conceive with mitochondrial donation. This technology is promising—but now is the time to start considering when and why it should be used.
Mitochondria,the small organelles that produce energy for our cells, are critically important for the proper growth and functioning of our bodies. When they fail to do their job, cells are starved of energy, which can have devastating effects. Mitochondrial...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...